275. Inside the VIKTORIA-1 trial with Dr. Rachel Layman
Dr. Rachel Layman explains the VIKTORIA-1 trial, focusing on genitolasib (G) for ER+/HER2- metastatic breast cancer. The discussion covers the PAM pathway, PIC3CA mutations, trial design, progression-free survival, side effects, and how patients can find clinical trials.